# Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors

> **NCT06238583** · — · NO_LONGER_AVAILABLE · sponsor: **Bayer**

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Copanlisib (Aliqopa, BAY80-6946)

## Key facts

- **NCT ID:** NCT06238583
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06238583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06238583, "Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06238583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*